Clin Exp Allergy:成年哮喘患者合并症分析!

2017-07-03 xing.T MedSci原创

由此可见,在成年哮喘患者中身体和心理健康合并症是正常的。适当的识别和治疗应成为常规哮喘护理的一部分。

哮喘患者合并症可显著增加哮喘发病率和降低哮喘指南的依从性。近日,过敏性疾病领域权威杂志Clinical and Experimental Allergy上发表了一篇研究文章,该研究的目的是通过一个全国性的具有代表性的人群来全面地测量成年哮喘患者的身体和心理健康合并症的患病率。

研究人员对英国1424378名成人常规初级护理电子病历进行横断面分析,并采用logistic回归对年龄、性别、社会剥夺和吸烟状况调整前后有无哮喘患者的39种合并症的患病率进行了调查。

在39个评估的合并症中,有36个(92%)在成年哮喘患者中更为常见。62.6%的成年哮喘患者有≥1个合并症 vs. 46.2%的无哮喘患者有≥1个合并症,16.3%的成年哮喘患者有≥4个合并症 vs. 8.7%的无哮喘患者有≥4个合并症。哮喘患者中患病率最大绝对增加的合并症为:慢性阻塞性肺病(13.4% vs. 3.1%)、抑郁(17.3% vs. 9.1%)、疼痛疾病(15.4% vs. 8.4%)和消化不良(10.9% vs. 5.2%)。在患有哮喘和无哮喘的患者间具有最大相对差异的合并症为:慢性阻塞性肺疾病(调整后的比值比[aOR]为5.65,95%CI为5.52-5.79)、支气管扩张症(aOR为4.65,95%CI为4.26-5.08)、湿疹/牛皮癣(aOR为3.30,95%CI为3.14-3.48)、消化不良(aOR为2.20,95%CI为2.15-2.25)和慢性鼻窦炎(aOR为2.12,95%CI为1.99-2.26)。抑郁和焦虑更常见于成年哮喘患者(分别有aOR为1.60,95%CI为1.57-1.63,aOR为1.53,95%CI为1.48-1.57)。

由此可见,在成年哮喘患者中身体和心理健康合并症是正常的。适当的识别和治疗应成为常规哮喘护理的一部分。

原始出处:

Christopher J Weatherburn,et al. Comorbidities in adults with asthma: population-based cross-sectional analysis of 1.4 million adults in Scotland.Clin Exp Allergy. 2017. http://onlinelibrary.wiley.com/doi/10.1111/cea.12971/full

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1825835, encodeId=febd1825835c5, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Thu Nov 09 12:00:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328987, encodeId=261b132898e43, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Jul 05 10:00:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218388, encodeId=3e2f2183883d, content=好好的学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jul 04 07:45:19 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218303, encodeId=584521830347, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Tue Jul 04 00:20:22 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218214, encodeId=da92218214c5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jul 03 20:13:26 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1825835, encodeId=febd1825835c5, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Thu Nov 09 12:00:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328987, encodeId=261b132898e43, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Jul 05 10:00:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218388, encodeId=3e2f2183883d, content=好好的学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jul 04 07:45:19 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218303, encodeId=584521830347, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Tue Jul 04 00:20:22 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218214, encodeId=da92218214c5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jul 03 20:13:26 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
    2017-07-05 膀胱癌
  3. [GetPortalCommentsPageByObjectIdResponse(id=1825835, encodeId=febd1825835c5, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Thu Nov 09 12:00:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328987, encodeId=261b132898e43, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Jul 05 10:00:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218388, encodeId=3e2f2183883d, content=好好的学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jul 04 07:45:19 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218303, encodeId=584521830347, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Tue Jul 04 00:20:22 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218214, encodeId=da92218214c5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jul 03 20:13:26 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
    2017-07-04 忠诚向上

    好好的学习一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1825835, encodeId=febd1825835c5, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Thu Nov 09 12:00:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328987, encodeId=261b132898e43, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Jul 05 10:00:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218388, encodeId=3e2f2183883d, content=好好的学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jul 04 07:45:19 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218303, encodeId=584521830347, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Tue Jul 04 00:20:22 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218214, encodeId=da92218214c5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jul 03 20:13:26 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
    2017-07-04 184****9840

    学习了谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1825835, encodeId=febd1825835c5, content=<a href='/topic/show?id=c52d388137b' target=_blank style='color:#2F92EE;'>#合并症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38813, encryptionId=c52d388137b, topicName=合并症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Thu Nov 09 12:00:00 CST 2017, time=2017-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1328987, encodeId=261b132898e43, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Wed Jul 05 10:00:00 CST 2017, time=2017-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218388, encodeId=3e2f2183883d, content=好好的学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jul 04 07:45:19 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218303, encodeId=584521830347, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5Kzuf9u71gZhPYMiajRtENwicoAABeQtfXOlic8ibhYSy6DvJZWUDVtjRvTfqBffr1XJ6JLtFB5kHicthl/0, createdBy=d41c2055892, createdName=184****9840, createdTime=Tue Jul 04 00:20:22 CST 2017, time=2017-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=218214, encodeId=da92218214c5, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Mon Jul 03 20:13:26 CST 2017, time=2017-07-03, status=1, ipAttribution=)]
    2017-07-03 清风拂面

    学习了,谢谢分享

    0

相关资讯

J Allergy Clin Immunol Pract:哮喘和枯草热对怀孕的影响

之前的研究表明,哮喘和不良妊娠结果有关。同时,在世界范围内,哮喘和枯草热的患者数目持续增长。最近,有研究人员探究了哮喘和/或者枯草热对怀孕结果是否有不良影响。数据来源于1995年的家庭成长国家调查,包括了美国人群中,具有代表性的10847名女性的诊断哮喘、枯草热和怀孕不良结果的历史资料,年龄在15岁到44岁之间,研究人员对这些数据进行了分析。研究发现,患有过敏性表型的哮喘和枯草热的女性在不良妊娠结

JACC: Heart Failure:哮喘患者更易罹患心血管疾病

一项最新研究首次发现了哮喘病史与左心室肥厚发生率增加有关,而后者是心力衰竭的一个危险因素。

SCI REP:阻塞性睡眠呼吸暂停与哮喘的关系分析!

这项研究表明哮喘患者阻塞性睡眠呼吸暂停的患病率相当高,甚至高于阻塞性睡眠呼吸暂停风险和SDB的患病率,对伴有阻塞性睡眠呼吸暂停/阻塞性睡眠呼吸暂停风险/SDB的哮喘患者应进行睡眠研究。

JACC-Heart Failure:哮喘可能与心衰有关

既往研究已经发现,哮喘与心脏病和脑卒中风险增加都有关。近期,一项发表在JACC心衰子刊上的研究发现,哮喘可能增加左心室肥厚风险,而后者是心衰的危险因素之一。

JACC:Heart Failure:哮喘患者更易罹患心血管疾病

一项最新研究首次发现了哮喘病史与左心室肥厚发生率增加有关,而后者是心力衰竭的一个危险因素。

Pediatr Pulmonol:支气管肺发育不良和哮喘儿童在激发试验、气道炎症和肺功能之间有何异同?

目前还没有建立对前早产儿支气管肺发育不良(BPD)的长期呼吸特征的研究。本研究的目的是描述与学龄儿童特应性哮喘相比,BPD的特征。研究结果发表在最新一期医学儿科知名期刊Pediatr Pulmonol上。